“The human brain is arguably the most complex structure on the planet. To create a novel chemical that has never existed before and administer it to the brain seems problematic to me. But what if we could take an inverted approach and examine how brain cells communicated in early evolving animals, then trace this mechanism to humans? This was our basic philosophy to discover novel therapeutics in humans.” – David Lovejoy, PhD
A founder of the company from the beginning in September 2004, Dr. Lovejoy holds a Ph.D. in Neuroendocrinology from the University of Victoria (Victoria, BC) and spent three years at the Clayton Foundation Laboratories for Peptide Biology at the Salk Institute (San Diego, CA) as a postdoctoral fellow. Dr. Lovejoy took his first academic appointment at the University of Manchester (Manchester, UK), one of the United Kingdom’s top-ranking research universities. He joined the University of Toronto (Toronto, Ontario) in 2000 and is currently Professor of Neuroendocrinology in the Department of Cell and Systems Biology at the University of Toronto. He is the author of more than 210 scientific publications including 3 books in the field and an Associate Editor for a scientific journal and is inventor or co-inventor on all of our intellectual property.
© 2022 Protagenic Therapeutics, Inc.
Built by Techtegic
